By VETTAPHARMA reporter: Basel, Switzerland, February 18, 2026 — Novartis announced that its investigational oral therapy remibrutinib has become the first treatment to achieve the primary endpoint in a Phase III study for chronic inducible urticaria (CIndU), a condition characterized by recurrent hives triggered by external stimuli.
“If approved, remibrutinib could represent the first targeted therapy specifically studied and proven effective in Phase III trials for chronic inducible urticaria.”
According to the company, the Phase III RemIND trial met its primary endpoint at Week 12, demonstrating a statistically significant improvement in complete response rates compared with placebo across the most common CIndU subtypes. These include symptomatic dermographism, cold urticaria and cholinergic urticaria.
Remibrutinib is described as a highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor designed to target underlying disease mechanisms involved in urticaria symptoms. The positive Phase III results mark a potential milestone for patients with CIndU, for whom treatment options remain limited and are often centered on antihistamines.
Novartis stated that detailed results from the study will be presented at upcoming scientific meetings. The company also indicated plans to share the data with regulatory authorities to support potential filings.
Source Credit:
- Novartis. (2026, February 18). Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU). Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
